###begin article-title 0
Genetic Polymorphisms in the EGFR (R521K) and Estrogen Receptor (T594T) Genes, EGFR and ErbB-2 Protein Expression, and Breast Cancer Risk in Tunisia
###end article-title 0
###begin p 1
Recommended by Peter J. Oefner
###end p 1
###begin p 2
###xml 709 710 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 741 742 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 830 831 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 966 967 966 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 976 977 976 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 322 330 <span type="species:ncbi:9606">patients</span>
###xml 672 680 <span type="species:ncbi:9606">patients</span>
###xml 1168 1176 <span type="species:ncbi:9606">patients</span>
We evaluated the association of epidermal growth factor receptor (EGFR) 142285G>A (R521K) and estrogen receptor alpha (ESR1) 2014G>A (T594T) single nucleotide polymorphisms with breast cancer risk and prognosis in Tunisian patients. EGFR 142285G>A and ESR1 2014G>A were genotyped in a sample of 148 Tunisian breast cancer patients and 303 controls using PCR-RFLP method. Immunohistochemitsry was used to evaluate the expression levels of EGFR, HER2, ESR1, progesterone receptor and BCL2 in tumors. We found no evidence for an association between EGFR R521K polymorphism and breast cancer risk. However, we found that the homozygous GG (Arg) genotype was more prevalent in patients with lymph node metastasis (P = .03) and high grade tumors (P = .011). The ESR1 2014G allele showed significant association with breast cancer risk (P = .025). The GG genotype was associated with HER2 overexpression and this association withstood univariate and multivariate analyses (P = .009; P = .021, resp.). These data suggest that the R521K might be a prognostic factor, because it correlates with both tumor grade and nodule status. The higher expression of HER2 in ESR1 T594T GG patients suggests the possibility that ESR1 gene polymorphisms accompanied by HER2 expression might influence the pathogenesis of breast cancers.
###end p 2
###begin title 3
1. Introduction
###end title 3
###begin p 4
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 598 602 598 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neu,</italic>
###xml 675 676 675 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
The epidermal growth factor receptor (EGFR, MIM: 131550), also known as HER-1 or ErbB-1, is the prototype member of the type I receptor tyrosine kinase (TK) family. It is a transmembrane protein with intrinsic tyrosine kinase activity, whose activation leads to downstream effects in gene expression, cellular proliferation, inhibition of apoptosis, and angiogenesis [1]. Exons 1-14 code for the extracellular domain, exon 15 encodes the transmembrane region, and exons 16-20 code for the intracellular tail. EGFR belongs to the ErbB family of TK receptors, whose other members include ErbB2 (HER2/neu, MIM: 164870), ErbB3 (HER3, MIM: 190151), and ErbB4 (HER4, MIM: 600543) [2]. 
###end p 4
###begin p 5
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 496 499 496 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 501 504 501 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fos</italic>
###xml 510 513 510 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">jun</italic>
###xml 515 516 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
A polymorphic variant in the EGFR gene arising from a single nucleotide substitution (142285G>A) leading to an Arginine (R)/Lysine (K) substitution in codon 521 in the extracellular subdomain IV of the EGFR gene (rs11543848, also known as HER-1 R497K) has been identified [3]. Compared with the "wild-type" HER-1 142285G (521R) allele, that the 142285A (521K) variant has attenuated function in ligand binding, growth stimulation, tyrosine kinase activation, and induction of the proto-oncogenes myc, fos, and jun [4]. 
###end p 5
###begin p 6
###xml 57 62 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 261 262 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 524 525 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 655 660 651 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 760 764 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 624 629 <span type="species:ncbi:9606">human</span>
 Among the steroid receptors, estrogen receptor alpha (ERalpha or ESR1, MIM: 133430) and the ER-regulated progesterone receptor (PGR, MIM: 607311) are of special interest because of their elevated protein levels in some premalignant and malignant breast cells [5]. ERs belong to a family of transcription factors, the nuclear receptor superfamily, responsible for mediating the effects of several hormone families including sex steroids on development, reproduction, proliferation, cellular homeostasis and gene expression [6]. There are two isoforms of ER, ESR1 and ESR2 (MIM: 601663), showing 47% sequence identity in the human genome. The ESR1 gene (ERalpha) located on chromosome 6q25-27 has eight exons and spans more than 140 kilobases. The ESR2 gene (ERbeta) located on chromosome 14q23-24 has also eight exons spanning approximately 40 kilobases. 
###end p 6
###begin p 7
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
 The overexpression of ERs in breast tumour tissues has been demonstrated to be a significant prognostic factor that correlates with higher survival rates and lower risk of relapse [7]. Inherited variants of the estrogen receptor gene have been observed to occur at increased rates in breast cancer [8]. One of the most studied polymorphism is the coding synonymous variant at codon 594 (rs2228480) within the last exon of the gene. This variant is thought to play a role in distinguishing between the receptor agonist or antagonists binding to the receptor molecule [9] and has been suggested, although inconsistently, to be associated with risk of breast cancer [10] and more recently of thyroid cancer [11]. 
###end p 7
###begin p 8
###xml 125 133 <span type="species:ncbi:9606">patients</span>
 In the present study, we analyzed the two above mentioned polymorphisms (EGFR 142285G>A; ESR1 2014G>A) in 148 breast cancer patients and 303 healthy individuals and investigated their association with breast cancer in order to evaluate their potential as prognostic/predictive factors.
###end p 8
###begin title 9
2. Materials and Methods
###end title 9
###begin title 10
2.1. Population Samples
###end title 10
###begin p 11
###xml 46 51 <span type="species:ncbi:9606">women</span>
###xml 202 210 <span type="species:ncbi:9606">patients</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
###xml 421 429 <span type="species:ncbi:9606">patients</span>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
The studied population comprised 148 Tunisian women with pathologically proven breast cancer selected from the register of Sfax University Hospital Habib Bourguiba between the years 2001 and 2006. Only patients that have complete clinical records and frozen tumor samples were included in the study. The average age was 49.9 +/- 11.4 (range 17-78 years). One hundred twenty nine patients had invasive ductal carcinoma, 6 patients had invasive lobular carcinoma and 10 patients had medullar or tubular cancers. Histological grade was not available for lobular carcinomas since tubule formation is not a characteristic of the tumour. 
###end p 11
###begin p 12
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 346 350 <span type="species:ncbi:9925">goat</span>
 The protein expression levels of EGFR, HER2, ESR1, PGR, and BCL2 (MIM: 151430) was assessed using immunohistochemistry on frozen tissue. Their primary antibody, (respectively: DM267/ACRIS, BM5084/ACRIS, clone 1D5/DAKO, clone PgR636/DAKO, clone 124/DAKO) were incubated during 30 minutes at room temperature, A biotin-labeled secondary antibody (goat antirabbit, DAKO, 1 : 500) was used for 15 minutes at room temperature. Then the avidin-biotin-HRP complex as directed by DAKO was applicated for 15 minutes, finally, the immunoprecipitate was visualised by treating with diaminobenzidine tetrahydrochloride (DAB) (DAKO) for 30 minutes. The sections were counterstaining with haematoxylin. Immunostaining was considered positive if more than 5% of tumour cells were stained and scored on the basis of the approximate percentage of positive tumours cells and the relative immunostaining intensity [12]. 
###end p 12
###begin p 13
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 253 254 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
Other variables such as tumour size (in cm), Scarff-Bloom-Richardson (SBR) grade and nodal status were also evaluated. Tumour grades were as follows: well-differentiated collectively referred to as SBR grade I (n = 9), grade II (n = 76), and grade III (n = 44) disease. The nodal status was known for 144 patients; 52 (36.1%) had no nodal involvement, lymph node invasion was detectable in 92 cases (63.8%). 51 had one to three nodes involved and 41 had more than three nodes involved. 
###end p 13
###begin p 14
 The control group comprised 303 individuals with no personal or familial history of cancer. The average age of controls was 61.7 +/- 9.7 (range 17-87) years.
###end p 14
###begin title 15
2.2. DNA Extraction and Genotyping
###end title 15
###begin p 16
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
DNA was extracted from frozen breast cancer tumours and peripheral blood samples of patients and controls using DNA purification kit (Promega, USA). DNA was also extracted from blood of sixty patients, for whom blood samples were available. 
###end p 16
###begin p 17
###xml 120 121 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 124 131 124 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MvaI</italic>
EGFR 142285G>A was genotyped by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method [3] (Table 1). The PCR product (155 bp) was digested by MvaI restriction enzyme (Fermentas, LIFE SCIENCES) at 37degreesC overnight. This restriction enzyme recognizes the sequence CC/WGG. The G-allele carrying PCR product is cleaved twice by the enzyme giving rise to three fragments (38, 50 and 67 bp), whereas the A allele is cleaved only once (38 and 117 bp). Digestion products were separated by electrophoresis on 4% Nusieve ethidium bromide-stained agarose gels and visualized under UV light. 
###end p 17
###begin p 18
###xml 42 44 42 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 47 54 47 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
ESR1 2014G>A was analysed using PCR-RFLP [10] (Table 1). The PCR products of 227 (bp) were then digested with BtgI (C/CRYGG) (New England Biolabs, Inc., USA) overnight at 37degreesC. The sizes of the restriction fragments of PCR product were 227 bp for the wild type homozygote (AA), 129 and 98 bp for the GG genotype and 227, 129 and 98 bp for the heterozygote (AG). 
###end p 18
###begin p 19
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
 Genotypes of tumour and blood samples from sixty patients were found to be identical. In data analysis, we considered only genotypes from tumours assuming them to be identical to blood DNA genotypes for all patients.
###end p 19
###begin title 20
2.3. Statistical Analysis
###end title 20
###begin p 21
###xml 123 136 123 136 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hwe, Conting </sc>
###xml 140 147 140 147 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Relrisk</sc>
###xml 245 248 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 248 249 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Differences in allele and genotype frequencies were evaluated by the Chi-square or Fisher exact test. We used the programs Hwe, Conting and Relrisk from linkage utility programs to test for Hardy-Weinberg equilibrium in control and to calculate chi2 tests for genotypic and allelic association and odds ratios (OR) with their 95% confidence intervals ().
###end p 21
###begin p 22
###xml 459 460 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Association between each of the SNP and clinicopathological parameters was assessed using chi-square test. To study correlation between clinical parameters and genotypes of EGFR and ESR1 polymorphisms in multivariate mode we used binary logistic regression with each parameter as dependent variable and genotypes of the two studied SNP together with other clinical parameters as independent variables. Statistical significance for all tests was declared when P-values are <.05.
###end p 22
###begin title 23
3. Results
###end title 23
###begin title 24
3.1. Association of Polymorphisms with Cancer Risk
###end title 24
###begin p 25
###xml 129 136 129 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Allelic and genotype frequencies of the two studied polymorphisms in patients (DNA from blood samples) and controls are given in Table 2. Genotype frequencies for rs11543848 and rs2228480 in controls agreed with frequencies expected under the Hardy-Weinberg equilibrium. 
###end p 25
###begin p 26
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R521K</italic>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
 Regarding EGFR R521K, genotype and allele frequencies were very similar between patients and controls. In both groups, about 60% of individuals were homozygous R/R, 32% were R/K heterozygotes and the remaining 8% carried the K/K genotype. 
###end p 26
###begin p 27
###xml 132 133 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 230 237 230 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
 Concerning the ESR1 codon 594 SNP, we found the frequency of the G allele to be significantly higher in patients than in controls (P = .025). The same trend, albeit barely significant, was observed for the GG genotype (P = .05) (Table 2). The ESR1 594 SNP provides 71% empirical power for association at 5% significance level calculated as described in Maalej et al. [13].
###end p 27
###begin title 28
###xml 56 64 <span type="species:ncbi:9606">Patients</span>
3.2. Association between SNP and Clinical Parameters in Patients
###end title 28
###begin p 29
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3 </xref>
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 477 478 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
Table 3 shows a significant association between EGFR R521K genotypes and SBR grade (P = .011) and Lymph-node status (P = .03). Genotypes RK and KK were more frequent in patients with positive nodal status and KK homozygotes were more prevalent in SBR grade III than in other tumours. In logistic regression analysis, the association between SBR grade and EGFR R521K genotype was even higher after adjustment for other clinical parameters and for the ESR1 2014G>A polymorphism (P = .008). The RR genotype seems to be associated with a good prognosis. 
###end p 29
###begin p 30
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 315 316 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
 No association was found between ESR1 T594T and any of the clinical parameters in this study, except the strong association revealed with HER2 status both in univariate (P = .009) and in multivariate analysis using logistic regression with HER2 status as dependent variable adjusting for other clinical variables (P = .021). However, multivariate analysis of nodal status detected a significant association with ESR1 T594T genotype (P = .041). It should be noted that genotype GG was more prevalent in tumours with positive HER2 compared to those with negative HER2 (82.4% versus 60%, resp.).
###end p 30
###begin title 31
4. Discussion
###end title 31
###begin p 32
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 797 799 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 708 716 <span type="species:ncbi:9606">patients</span>
Cancer is a complex disease where genetic mutations, deletions, rearrangement, or deletions as well as gene polymorphisms of other genes may affect not only cancer development but also cancer progression and as a result could influence cancer phenotypes [14]. In this study we investigated two polymorphisms within the EGFR and ESR1 genes that are known to play a key role in breast cancer onset and progression. EGFR is frequently overexpressed in a wide variety of solid tumors and is a target for cancer drugs [15]. The possibility that different genetic polymorphisms in the EGFR gene may regulate, at least in part, EGFR expression and/or activity, is an attractive hypothesis that may help to identify patients whose tumours are likely to respond to EGFR-targeted therapies or radiotherapy [16]. 
###end p 32
###begin p 33
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 206 214 <span type="species:ncbi:9606">Patients</span>
 Among the most interesting polymorphisms, the EGFR variant R521K has been previously described to be associated with cancer severity in other EGFR expressing tumours, such as gliomas and lung cancer [17]. Patients with rectal cancer carrying the R allele tended to have a higher risk of local recurrence [3, 18]. 
###end p 33
###begin p 34
###xml 169 177 <span type="species:ncbi:9606">patients</span>
 In our population-based case-control study, we found no evidence for an association between R521K and breast cancer risk. The frequency of the K allele in controls and patients was very similar (25.5% versus 23.6%). According to the SNP database, the frequency of the K allele in our population is similar to that in Europeans (25%). In comparison, its reported frequency in African-American, Subsaharan-African, and Asians is 10.9%, 16% and 45.1%, respectively. 
###end p 34
###begin p 35
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
 We found a significant correlation between R521K genotype distribution and SBR grades I and II (P = .011) and lymph node metastasis (P = .03). The association between EGFR variant R521K and lymph node metastasis deserves further consideration in future studies as a clinical indicator during presurgical evaluation; in fact, various studies of lymph node metastasis have considered factors such as intrinsic genetic factors involving cell mobility, vascular invasion and angiogenesis [19, 20]. 
###end p 35
###begin p 36
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 235 243 <span type="species:ncbi:9606">patients</span>
###xml 392 400 <span type="species:ncbi:9606">patients</span>
 The R521K EGFR genotype correlates with a decrease in EGFR phosphorylation, decreased invasion, lower nodal involvement, reduced subsequent metastasis, and longer disease-free and overall survival in stage II/III colorectal carcinoma patients who have received curative surgery [18]. Zhang et al. [3] reported that EGFR polymorphism R521K was negatively associated with pelvic recurrence in patients with rectal cancer treated with chemoradiation. 
###end p 36
###begin p 37
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 530 531 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
 The second SNP that we investigate here is the synonymous codon T594T A/G transition in the ESR1 gene. Estrogen receptor alpha gene (ESR1) has been implicated in the initiation and development of breast cancer. Since it is an important mediator of the hormonal response in estrogen-sensitive tissues, ESR1 polymorphism was postulated to be potential risk factor of breast cancer [21]. We found here a significant association of G variant with breast cancer risk. This result is in agreement with reports in European populations [8] but this association was not reported in the Turkish population [10]. 
###end p 37
###begin p 38
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 127 132 <span type="species:ncbi:9606">human</span>
 The expression of HER2 was more pronounced in the presence of the ESR1 GG genotype. The cytoplasmic overexpression of HER2 in human breast cancer is considered to be a poor prognostic factor [22]. It was reported that the HER2 gene harbours an estrogen-responsive element ERE [23] in its regulatory region. Since the polymorphism ESR1 codon 594 was hypothesized to be associated with altered receptor expression and function [24, 25] this might explain its relation to HER2 expression level. The increased expression of ErbB-2 and the EGFR external domain in the presence of the GG genotype might provide an increased risk for breast cancer. Polymorphisms of the ESR1 genes have been suggested to be associated with the occurrence of several disorders [26, 27], including breast cancer [28, 29]. 
###end p 38
###begin p 39
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
 In multivariate analysis a significant association was found between ESR1 codon 594 and lymph node status in Tunisian population. A similar result was reported in Taiwanese population [20]. This suggests that this marker would be a good predictor of nodal status prior to surgical intervention and thereby provides an indicator for deciding whether chemotherapy should be given or not.
###end p 39
###begin title 40
5. Conclusion
###end title 40
###begin p 41
###xml 40 47 <span type="species:ncbi:9606">patient</span>
In summary, in a Tunisian breast cancer patient population, a significant association was found between SNP R521K of EGFR (rs2227983) and SBR grade as well as with Lymph-node status, suggesting that this polymorphism might be clinically important in prognosis. The association of ESR1 polymorphisms with breast cancer risk and HER2 expression but not with other clinical parameters might reflect that it plays a role in the pathogenic processes resulting in the development of breast cancer. With multivariate analysis a correlation between Lymph node metastasis and GG genotype of ESR1 2014G>A (T594T) was found. Validation and functional studies are needed to assess the significance of these associations in clinical practice.
###end p 41
###begin title 42
Acknowledgment
###end title 42
###begin p 43
This work was supported by the Ministry of Higher Education, Scientific Research, and Technology, Tunisia.
###end p 43
###begin article-title 44
Epidermal growth factor receptor: a promising target in solid tumours
###end article-title 44
###begin article-title 45
The ErbB signalling network: receptor heterodimerization in development and cancer
###end article-title 45
###begin article-title 46
###xml 131 139 <span type="species:ncbi:9606">patients</span>
Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer
###end article-title 46
###begin article-title 47
###xml 65 70 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling
###end article-title 47
###begin article-title 48
###xml 23 28 <span type="species:ncbi:9606">human</span>
Biological features of human premalignant breast disease
###end article-title 48
###begin article-title 49
###xml 53 58 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 63 67 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 79 84 <span type="species:ncbi:9606">human</span>
Structure-function relationship of estrogen receptor alpha and beta: impact on human health
###end article-title 49
###begin article-title 50
###xml 160 168 <span type="species:ncbi:9606">patients</span>
Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06
###end article-title 50
###begin article-title 51
Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer
###end article-title 51
###begin article-title 52
###xml 115 120 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 125 129 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
Estrogen receptor antibodies: specificity and utility in detection, localization and analyses of estrogen receptor alpha and beta
###end article-title 52
###begin article-title 53
Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk
###end article-title 53
###begin article-title 54
Association of polymorphisms in oestrogen and thyroid hormone receptors with thyroid cancer risk
###end article-title 54
###begin article-title 55
Similar BCL-X but different BCL-2 levels in the two age groups of North African nasopharyngeal carcinomas
###end article-title 55
###begin article-title 56
Lack of association of VDR gene polymorphisms with thyroid autoimmune disorders: familial and case/control studies
###end article-title 56
###begin article-title 57
Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer
###end article-title 57
###begin article-title 58
###xml 37 42 <span type="species:ncbi:4502">chess</span>
ErbB antagonists patenting: "playing chess with cancer"
###end article-title 58
###begin article-title 59
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients
###end article-title 59
###begin article-title 60
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium trials 01-03 and 00-01
###end article-title 60
###begin article-title 61
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma
###end article-title 61
###begin article-title 62
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
###end article-title 62
###begin article-title 63
###xml 18 23 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Estrogen receptor-alpha polymorphism in a Taiwanese clinical breast cancer population: a case-control study
###end article-title 63
###begin article-title 64
###xml 36 41 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 55 60 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China
###end article-title 64
###begin article-title 65
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
###end article-title 65
###begin article-title 66
SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens
###end article-title 66
###begin article-title 67
###xml 32 37 <span type="species:ncbi:9606">human</span>
Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism
###end article-title 67
###begin article-title 68
###xml 81 86 <span type="species:ncbi:9606">women</span>
Vitamin D receptor genotypes and intestinal calcium absorption in postmenopausal women
###end article-title 68
###begin article-title 69
Estrogen receptor gene polymorphism and generalized osteoarthritis
###end article-title 69
###begin article-title 70
Association of bone mineral density with polymorphism of estrogen receptor gene
###end article-title 70
###begin article-title 71
Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility
###end article-title 71
###begin article-title 72
###xml 98 103 <span type="species:ncbi:9606">human</span>
Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers
###end article-title 72
###begin p 73
Position of SNP and enzyme and primers used in this study.
###end p 73
###begin p 74
*gene names according to gene database in NCBI: . 
###end p 74
###begin p 75
**rs code in dbSNP .
###end p 75
###begin p 76
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Allelic and genotype distribution frequencies of R521K and T594T polymorphism in the patients and the control groups.
###end p 76
###begin p 77
Association between EGFR and ESR1 genotype with EGFR, HER2, ER, PR, and BCL2 protein expression and clinical parameters.
###end p 77

